Altimmune is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with an additional operating site in London, UK. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer, with the potential for fundamental advantages over competing products.

ALT (Common Stock)
$2.05
Change (%) Stock is Down 0.12 (5.53%)
Volume27,192
Data as of 08/17/17 2:33 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delay
Refresh quote
Stock chart for: ALT.O.  Currently trading at $2.05 with a 52 week high of $14.70 and a 52 week low of $2.04.

Primary IR Contact

Matthew Duffy
Phone: (212) 915-0685
E-mail: matthew@lifesciadvisors.com

Upcoming Events

August 10, 2017 8:30 a.m. ETSecond Quarter 2017 Earnings Conference Call
June 19, 2017 through June 20, 2017Altimmune, Inc. at the BIO International Convention

Altimmune is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer, with the potential for fundamental advantages over competing products.

© 2017 Altimmune, Inc.   All rights reserved.   Terms of Use